Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03602079
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:38.826426+00:00
Published At
2023-08-03T00:00:00+00:00
Record Updated At
2023-08-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-08-03"
protocolSection.identificationModule.nctId
"NCT03602079"
protocolSection.identificationModule.officialTitle
"A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • HER-2 Gene Amplification (protocolSection.conditionsModule.conditions)
  • HER2 Positive Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Salivary Gland Cancer (protocolSection.conditionsModule.conditions)
  • Salivary Gland Tumor (protocolSection.conditionsModule.conditions)
  • Salivary Gland Carcinoma (protocolSection.conditionsModule.conditions)
  • Salivary Gland Neoplasms (protocolSection.conditionsModule.conditions)
  • Lung Cancer (protocolSection.conditionsModule.conditions)
  • Colo-rectal Cancer (protocolSection.conditionsModule.conditions)
  • Rare Diseases (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Colon Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Cancer (protocolSection.conditionsModule.conditions)
  • Head and Neck Carcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Liver Cancer (protocolSection.conditionsModule.conditions)
  • Bile Duct Cancer (protocolSection.conditionsModule.conditions)
  • Urologic Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Rectal Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Rectal Cancer Stage II (protocolSection.conditionsModule.conditions)
  • Rectal Cancer Stage I (protocolSection.conditionsModule.conditions)
  • Rectal Cancer Stage III (protocolSection.conditionsModule.conditions)
  • Skin Cancer (protocolSection.conditionsModule.conditions)
  • Mouth Cancer (protocolSection.conditionsModule.conditions)
  • Lip Cancer Stage I (protocolSection.conditionsModule.conditions)
  • Tongue Cancer (protocolSection.conditionsModule.conditions)
  • Breast Neoplasm Malignant Primary (protocolSection.conditionsModule.conditions)
  • Larynx Cancer (protocolSection.conditionsModule.conditions)
  • Tonsil Cancer (protocolSection.conditionsModule.conditions)
  • Palate Cancer (protocolSection.conditionsModule.conditions)
  • Mucoepidermoid Carcinoma (protocolSection.conditionsModule.conditions)
  • Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Mucinous Adenocarcinoma Gastric (protocolSection.conditionsModule.conditions)
  • Mucinous Breast Cancer Recurrent (protocolSection.conditionsModule.conditions)
  • Cholangiocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.